Evidence-Based Pharmacist Care (Clinical, Economic, and Humanistic Impact): Malaria

Malaria continues to impose a heavy global burden, with over 200 million cases and hundreds of thousands of deaths annually. This chapter synthesizes high-quality evidence demonstrating how pharmacist-led interventions mitigate clinical, economic, and humanistic impacts of malaria. Clinically, pharmacists optimize antimalarial selection and dosing via stewardship programs, therapeutic drug monitoring, and point-of-care testing, reducing symptom severity, complications, and mortality. Economically, strategies such as generic substitution, IV-to-oral transitions, medication-use evaluations, and adherence support yield substantial cost savings by shortening hospital stays, preventing readmissions, and minimizing drug wastage. From a humanistic perspective, tailored patient education on prophylaxis, symptom management, and preventive measures enhances quality of life, self-efficacy, and treatment satisfaction. Literature confirm improvements in clinical outcomes, per-patient cost reductions, and patient-reported well-being. Facilitators—interdisciplinary collaboration, digital health 118 tools, and continuous professional development—are identified, alongside barriers like regulatory constraints and reimbursement challenges. Standardized metrics and implementation frameworks are proposed to guide the sustainable integration of evidence-based pharmacist care into malaria management.